Patents by Inventor Mario Mautino
Mario Mautino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11485705Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: GrantFiled: May 22, 2020Date of Patent: November 1, 2022Assignee: LUMOS PHARMA, INC.Inventors: Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
-
Publication number: 20200283385Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: ApplicationFiled: May 22, 2020Publication date: September 10, 2020Inventors: Mario MAUTINO, Sanjeev KUMAR, Firoz JAIPURI, Jesse WALDO, Hima POTTURI, Hong ZHUANG
-
Publication number: 20190248739Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: ApplicationFiled: February 15, 2019Publication date: August 15, 2019Inventors: Mario MAUTINO, Sanjeev KUMAR, Firoz JAIPURI, Jesse WALDO, Hima POTTURI, Hong ZHUANG
-
Publication number: 20190225618Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: ApplicationFiled: February 7, 2019Publication date: July 25, 2019Inventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Patent number: 10233190Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.Type: GrantFiled: November 1, 2017Date of Patent: March 19, 2019Assignee: NEWLINK GENETICS CORPORATIONInventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Patent number: 10207990Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: GrantFiled: June 27, 2017Date of Patent: February 19, 2019Assignee: NEWLINK GENETICS CORPORATIONInventors: Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
-
Patent number: 10047066Abstract: Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprisType: GrantFiled: December 1, 2008Date of Patent: August 14, 2018Assignee: NEWLINK GENETICS CORPORATIONInventors: Mario Mautino, Firoz Jaipuri, Agnieszka Marcinowicz-Flick, Tanay Kesharwani, Jesse Waldo
-
Patent number: 9981973Abstract: Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: GrantFiled: February 16, 2017Date of Patent: May 29, 2018Assignee: NEWLINK GENETICS CORPORATIONInventors: Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Mario Mautino
-
Publication number: 20180134658Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: ApplicationFiled: June 27, 2017Publication date: May 17, 2018Inventors: Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
-
Publication number: 20180118753Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.Type: ApplicationFiled: November 1, 2017Publication date: May 3, 2018Inventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Patent number: 9850248Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: GrantFiled: June 13, 2016Date of Patent: December 26, 2017Assignee: NewLink Genetics CorporationInventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Publication number: 20170260188Abstract: Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.Type: ApplicationFiled: February 16, 2017Publication date: September 14, 2017Inventors: Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Mario Mautino
-
Patent number: 9732035Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: GrantFiled: June 2, 2016Date of Patent: August 15, 2017Assignee: NEWLINK GENETICS CORPORATIONInventors: Mario Mautino, Sanjeev Kumar, Firoz Jaipuri, Jesse Waldo, Hima Potturi, Hong Zhuang
-
Patent number: 9617272Abstract: Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: GrantFiled: March 10, 2014Date of Patent: April 11, 2017Assignee: NewLink Genetics CorporationInventors: Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Mario Mautino
-
Publication number: 20170022157Abstract: Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.Type: ApplicationFiled: June 2, 2016Publication date: January 26, 2017Inventors: Mario MAUTINO, Sanjeev KUMAR, Firoz JAIPURI, Jesse WALDO, Hima POTTURI, Hong ZHUANG
-
Publication number: 20160362412Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.Type: ApplicationFiled: August 26, 2016Publication date: December 15, 2016Inventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Patent number: 9388191Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: GrantFiled: July 8, 2015Date of Patent: July 12, 2016Assignee: NewLink Genetics CorporationInventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Publication number: 20160060266Abstract: Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: ApplicationFiled: March 10, 2014Publication date: March 3, 2016Inventors: Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Mario Mautino
-
Patent number: 9260434Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.Type: GrantFiled: October 14, 2013Date of Patent: February 16, 2016Assignee: NewLink Genetics CorporationInventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang
-
Publication number: 20160002249Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.Type: ApplicationFiled: July 8, 2015Publication date: January 7, 2016Inventors: Mario Mautino, Sanjeev Kumar, Jesse Waldo, Firoz Jaipuri, Tanay Kesharwani, Xiaoxia Zhang